,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,LCT,,ENSG00000115850,Lactase,2,135787840-135837180,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,631,duodenum: 223.1;small intestine: 142.8,"appendix,lymph node: 0.2",Cell line enhanced,,MOLT-4: 3.9;RPMI-8226: 6.7
1,DEFA6,"DEF6, HD-6",ENSG00000164822,Defensin alpha 6,8,6924693-6926076,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA019462,Enhanced,,,,,Tissue enhanced,Group enriched,525,duodenum: 5743.0;small intestine: 10524.2,colon: 15.4,Group enriched,9.0,BEWO: 28.1;NB-4: 20.0;RPMI-8226: 25.8;SH-SY5Y: 26.0;U-2197: 10.6
2,DEFA5,"DEF5, HD-5",ENSG00000164816,Defensin alpha 5,8,7055304-7056734,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA015775, CAB069919",Enhanced,,,,Colorectal cancer:9.44e-5 (favourable),Tissue enhanced,Group enriched,480,duodenum: 10677.9;small intestine: 19102.0,appendix: 31.0,Group enriched,6.0,BEWO: 55.6;NB-4: 31.4;RPMI-8226: 35.9;SH-SY5Y: 42.9;U-2197: 16.2
3,CCL25,"Ckb15, SCYA25, TECK",ENSG00000131142,C-C motif chemokine ligand 25,19,8052767-8062650,Predicted secreted proteins,Evidence at protein level,HPA055883,Uncertain,,,,,Group enriched,Group enriched,317,duodenum: 529.5;small intestine: 653.7,lymph node: 1.8,Cell line enhanced,,BEWO: 2.7;HEL: 2.7;REH: 5.6;SH-SY5Y: 2.0
4,RBP2,"CRABP-II, CRBP2, CRBPII, RBPC2",ENSG00000114113,Retinol binding protein 2,3,139452884-139480747,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA035866,Enhanced,,Approved,Golgi apparatus,,Tissue enhanced,Group enriched,204,duodenum: 2746.0;small intestine: 2037.7,lung: 11.7,Cell line enriched,6.0,CACO-2: 65.5
5,CYP3A4,CYP3A3,ENSG00000160868,Cytochrome P450 family 3 subfamily A member 4,7,99756960-99784265,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB033671, HPA072245",Enhanced,,Uncertain,Cytosol,,Tissue enriched,Group enriched,199,duodenum: 826.8;liver: 2451.8;small intestine: 971.1,adrenal gland: 7.1,Cell line enhanced,,BEWO: 1.8;NB-4: 1.3;RPMI-8226: 2.2;SCLC-21H: 1.4;SH-SY5Y: 2.4
6,MS4A10,"CD20L7, MS4A9",ENSG00000172689,Membrane spanning 4-domains A10,11,60785348-60801305,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA014778,Uncertain,,,,,Not detected,Group enriched,193,duodenum: 74.2;small intestine: 95.8,kidney: 0.4,Not detected,,
7,GIP,,ENSG00000159224,Gastric inhibitory polypeptide,17,48958554-48968596,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB016729, HPA021612",Enhanced,,,,,Tissue enriched,Group enriched,156,duodenum: 261.3;small intestine: 93.9,stomach: 1.1,Cell line enhanced,,A549: 6.0;BEWO: 5.7;Hep G2: 6.5
8,APOA4,,ENSG00000110244,Apolipoprotein A4,11,116820700-116823306,"Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001352, HPA002549, CAB068250, CAB068251, CAB068252",Enhanced,,Approved,Vesicles,,Tissue enriched,Group enriched,126,duodenum: 2211.8;small intestine: 3441.1,liver: 22.3,Cell line enhanced,,BEWO: 7.4;CACO-2: 6.6;Hep G2: 5.1;NB-4: 4.6;RPMI-8226: 8.2;SH-SY5Y: 11.1
9,APOB,,ENSG00000084674,Apolipoprotein B,2,21001429-21044073,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB016070, HPA049793",Supported,,Supported,Vesicles<br>Cytosol,,Tissue enriched,Group enriched,120,duodenum: 182.8;liver: 618.9;small intestine: 333.2,adipose tissue: 3.1,Cell line enriched,25.0,Hep G2: 734.4
10,CREB3L3,CREB-H,ENSG00000060566,CAMP responsive element binding protein 3 like 3,19,4153601-4173054,"Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,"HPA040671, HPA056228",Enhanced,,,,Renal cancer:3.53e-6 (unfavourable),Tissue enriched,Group enriched,104,duodenum: 241.6;liver: 61.0;small intestine: 278.7,"colon,stomach: 1.8",Cell line enhanced,,HDLM-2: 44.9;Hep G2: 10.3;U-266/70: 7.7
11,C17orf78,FLJ39647,ENSG00000278505,Chromosome 17 open reading frame 78,17,37375986-37392708,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Group enriched,Group enriched,74,duodenum: 99.1;small intestine: 50.9,testis: 1.0,Not detected,,
12,REG3A,"HIP, PAP, PAP1, PBCGF, REG-III, REG3",ENSG00000172016,Regenerating family member 3 alpha,2,79157003-79159753,"Plasma proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA047894, HPA048334, HPA060705",Supported,,Approved,Cytosol,,Tissue enhanced,Group enriched,56,duodenum: 5635.7;small intestine: 8081.8,stomach: 122.0,Cell line enhanced,,BEWO: 18.5;EFO-21: 17.0;HDLM-2: 16.3;RPMI-8226: 17.5;SH-SY5Y: 16.7;U-2 OS: 30.9
13,MEP1A,PPHA,ENSG00000112818,Meprin A subunit alpha,6,46793390-46839782,"Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB025163, HPA029416",Enhanced,,,,,Tissue enriched,Group enriched,42,colon: 117.8;duodenum: 282.2;rectum: 114.3;small intestine: 538.5,appendix: 6.2,Cell line enhanced,,BEWO: 1.2;CACO-2: 2.4;RPMI-8226: 1.0
14,MEP1B,,ENSG00000141434,Meprin A subunit beta,18,32185069-32220404,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA029119,Enhanced,,,,,Group enriched,Group enriched,37,duodenum: 251.4;small intestine: 402.2,colon: 8.7,Cell line enhanced,,SCLC-21H: 6.6
15,ISX,RAXLX,ENSG00000175329,Intestine specific homeobox,22,35066136-35087387,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA060328,Approved,,Supported,Nucleoplasm<br>Nuclear bodies,,Tissue enhanced,Group enriched,36,colon: 27.4;duodenum: 37.5;rectum: 28.2;small intestine: 29.7,smooth muscle: 0.8,Group enriched,12.0,CACO-2: 1.3;Hep G2: 3.1
16,TM4SF20,"FLJ22800, TCCE518",ENSG00000168955,Transmembrane 4 L six family member 20,2,227362156-227381995,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA051838, HPA063184, HPA065531",Uncertain,,Supported,Plasma membrane<br>Focal adhesion sites,,Group enriched,Group enriched,35,duodenum: 277.2;small intestine: 163.8,testis: 6.3,Cell line enhanced,,A549: 2.5;RPMI-8226: 1.2
17,TM4SF4,il-TMP,ENSG00000169903,Transmembrane 4 L six family member 4,3,149473974-149503281,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA046430,Enhanced,,Approved,Plasma membrane<br>Cytosol,,Group enriched,Group enriched,34,duodenum: 579.6;gallbladder: 1319.6;liver: 346.9;small intestine: 504.0,stomach: 20.2,Group enriched,6.0,A549: 19.4;RPTEC TERT1: 24.4
18,UGT1A1,"GNT1, UGT1, UGT1A",ENSG00000241635,UDP glucuronosyltransferase family 1 member A1,2,233760248-233773299,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,33,duodenum: 199.5;liver: 155.8;small intestine: 81.9,kidney: 4.3,Cell line enhanced,,HaCaT: 12.7;PC-3: 6.0;RT4: 27.4
19,ABCG5,STSL,ENSG00000138075,ATP binding cassette subfamily G member 5,2,43812472-43838865,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA016514,,,Approved,Nucleus,Liver cancer:2.60e-5 (favourable),Tissue enriched,Group enriched,32,duodenum: 56.5;liver: 28.4;small intestine: 56.2,gallbladder: 1.4,Cell line enriched,37.0,Hep G2: 6.3
20,ALPI,,ENSG00000163295,"Alkaline phosphatase, intestinal",2,232456123-232460032,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA038764, HPA038765, HPA051699",Supported,,Approved,Plasma membrane,,Tissue enhanced,Group enriched,31,duodenum: 203.2;small intestine: 212.1,colon: 6.6,Cell line enriched,10.0,CACO-2: 5.9
21,SLC10A2,"ASBT, ISBT",ENSG00000125255,Solute carrier family 10 member 2,13,103043998-103066846,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA004795,Approved,,,,Renal cancer:5.78e-5 (favourable),Tissue enriched,Group enriched,31,duodenum: 21.0;kidney: 15.4;small intestine: 51.4,gallbladder: 0.9,Not detected,,
22,ERICH4,"C19orf69, LOC100170765",ENSG00000204978,Glutamate rich 4,19,41443158-41444765,Predicted intracellular proteins,Evidence at transcript level,"HPA042632, HPA048484",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,27,duodenum: 42.8;kidney: 16.3;small intestine: 42.9,lung: 1.2,Group enriched,13.0,CACO-2: 2.1;Hep G2: 4.2;THP-1: 1.1
23,TBX10,"TBX13, TBX7",ENSG00000167800,T-box 10,11,67631303-67639560,"Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA047881,Uncertain,,,,,Group enriched,Group enriched,27,colon: 8.8;duodenum: 5.8;rectum: 8.6;small intestine: 10.6,appendix: 0.3,Cell line enhanced,,NTERA-2: 5.3;RPMI-8226: 2.5;SK-BR-3: 9.3;U-2 OS: 2.7
24,OTC,,ENSG00000036473,Ornithine carbamoyltransferase,X,38352545-38421450,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000243, HPA000570",Enhanced,,Supported,Mitochondria,,Tissue enriched,Group enriched,26,duodenum: 114.4;liver: 195.4;small intestine: 96.9,colon: 5.3,Not detected,,
25,SLC28A1,CNT1,ENSG00000156222,Solute carrier family 28 member 1,15,84884654-84945796,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA019551,Enhanced,,,,,Group enriched,Group enriched,26,duodenum: 37.9;kidney: 49.4;liver: 35.4;small intestine: 53.6,placenta: 1.7,Not detected,,
26,ABCG8,GBD4,ENSG00000143921,ATP binding cassette subfamily G member 8,2,43838964-43878466,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA019556,Uncertain,,Approved,Vesicles,,Tissue enriched,Group enriched,25,duodenum: 50.0;liver: 34.0;small intestine: 55.5,gallbladder: 1.8,Cell line enriched,44.0,Hep G2: 6.9
27,BTNL3,"BTN9.1, BTNLR",ENSG00000168903,Butyrophilin like 3,5,180988845-181006727,Predicted membrane proteins,Evidence at transcript level,,,,,,,Group enriched,Group enriched,25,colon: 24.5;duodenum: 115.1;rectum: 26.3;small intestine: 89.1,gallbladder: 2.5,Not detected,,
28,ALDOB,,ENSG00000136872,"Aldolase, fructose-bisphosphate B",9,101420578-101435823,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002198, CAB020827",Enhanced,,,,,Tissue enriched,Group enriched,23,duodenum: 3705.7;kidney: 6574.8;liver: 5092.2;small intestine: 5611.2,gallbladder: 231.1,Cell line enhanced,,BEWO: 16.8;NB-4: 10.8;RPMI-8226: 13.6;SH-SY5Y: 17.3
29,CEACAM20,UNQ9366,ENSG00000273777,Carcinoembryonic antigen related cell adhesion molecule 20,19,44501677-44529788,Predicted membrane proteins,Evidence at transcript level,,,,,,,Group enriched,Group enriched,23,duodenum: 38.8;prostate: 14.3;small intestine: 42.7,gallbladder: 1.3,Cell line enriched,7.0,U-266/70: 1.0
30,CPS1,,ENSG00000021826,Carbamoyl-phosphate synthase 1,2,210477682-210679107,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB003781, HPA021400",Enhanced,,Approved,Nucleoli,Liver cancer:6.93e-5 (favourable),Tissue enriched,Group enriched,23,duodenum: 234.5;liver: 697.8;small intestine: 144.1,testis: 15.3,Cell line enhanced,,HeLa: 249.1;SK-BR-3: 84.1
31,TMIGD1,"TMIGD, UNQ9372",ENSG00000182271,Transmembrane and immunoglobulin domain containing 1,17,30316333-30334059,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA021946,,,Approved,Mitochondria,,Tissue enhanced,Group enriched,23,colon: 81.8;rectum: 109.8;small intestine: 162.9,kidney: 5.1,Not detected,,
32,CUBN,"gp280, IFCR, MGA1",ENSG00000107611,Cubilin,10,16823964-17129831,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA004133, HPA043854",Enhanced,,,,Renal cancer:1.12e-4 (favourable),Tissue enriched,Group enriched,22,kidney: 153.7;small intestine: 54.4,thyroid gland: 4.7,Cell line enhanced,,AN3-CA: 14.6;WM-115: 5.9
33,ENPP7,"alk-SMase, NPP7",ENSG00000182156,Ectonucleotide pyrophosphatase/phosphodiesterase 7,17,79730919-79742222,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA024603,Approved,,,,,Tissue enriched,Group enriched,22,duodenum: 45.7;small intestine: 110.2,kidney: 3.5,Cell line enhanced,,Karpas-707: 1.4;U-266/70: 2.1
34,APOBEC1,"APOBEC-1, BEDP, CDAR1, HEPR",ENSG00000111701,Apolipoprotein B mRNA editing enzyme catalytic subunit 1,12,7649400-7665903,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,21,duodenum: 31.9;small intestine: 31.0,stomach: 1.5,Cell line enriched,17.0,CAPAN-2: 2.4
35,SLC6A19,,ENSG00000174358,Solute carrier family 6 member 19,5,1201595-1225117,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA037415, HPA043207",Enhanced,,Approved,Nucleoli,Renal cancer:4.14e-6 (favourable),Tissue enhanced,Group enriched,21,duodenum: 139.5;kidney: 91.8;small intestine: 156.9,rectum: 6.2,Group enriched,6.0,BEWO: 13.7;HEL: 16.3
36,ITLN2,HL-2,ENSG00000158764,Intelectin 2,1,160945025-160954799,Predicted secreted proteins,Evidence at protein level,"HPA006683, HPA067326",Enhanced,,,,,Tissue enhanced,Group enriched,19,duodenum: 244.7;small intestine: 454.0,lung: 18.2,Cell line enhanced,,HEL: 10.8;HMC-1: 3.0;SK-MEL-30: 3.0
37,ASIC5,"ACCN5, HINAC, INAC",ENSG00000256394,Acid sensing ion channel subunit family member 5,4,155829729-155866273,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA014903, HPA029444",Approved,,,,,Not detected,Group enriched,18,duodenum: 2.3;small intestine: 1.2,all non-specific tissues: 0.0,Not detected,,
38,ASAH2,,ENSG00000188611,N-acylsphingosine amidohydrolase 2,10,50182778-50248610,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA061171,Supported,,Approved,Focal adhesion sites,,Mixed,Group enriched,17,duodenum: 83.5;small intestine: 71.3,stomach: 4.6,Mixed,,
39,CLDN15,,ENSG00000106404,Claudin 15,7,101232092-101238820,"Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,"Renal cancer:5.31e-5 (unfavourable), Pancreatic cancer:2.56e-4 (favourable), Urothelial cancer:3.30e-4 (favourable)",Expressed in all,Group enriched,16,duodenum: 241.3;small intestine: 183.5,spleen: 13.3,Expressed in all,,
40,MTTP,"ABL, MTP",ENSG00000138823,Microsomal triglyceride transfer protein,4,99563761-99623999,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA051170, HPA054862",Uncertain,,Approved,Cytosol,,Tissue enriched,Group enriched,16,duodenum: 236.3;liver: 133.9;small intestine: 292.6,testis: 13.5,Cell line enhanced,,AF22: 10.2;Hep G2: 8.0
41,GUCA2A,"GUCA2, STARA",ENSG00000197273,Guanylate cyclase activator 2A,1,42162691-42164718,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA018215,Enhanced,,,,,Group enriched,Group enriched,15,colon: 768.8;rectum: 859.2;small intestine: 1127.0,duodenum: 61.5,Cell line enhanced,,BEWO: 11.8;CACO-2: 8.2;NB-4: 2.0;U-2197: 2.5
42,PYY,PYY1,ENSG00000131096,Peptide YY,17,43952738-44004469,Predicted secreted proteins,Evidence at protein level,"HPA010973, CAB016734",Enhanced,,,,,Group enriched,Group enriched,15,colon: 52.6;rectum: 39.2;small intestine: 27.4,duodenum: 2.5,Cell line enhanced,,HMC-1: 2.6
43,SI,,ENSG00000090402,Sucrase-isomaltase,3,164978898-165078495,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA011897,Enhanced,,,,,Tissue enhanced,Group enriched,15,duodenum: 547.3;small intestine: 493.2,rectum: 34.5,Cell line enhanced,,BEWO: 1.0;CACO-2: 1.3;RPMI-8226: 1.3;SH-SY5Y: 1.2
44,SLC34A3,"FLJ38680, NPTIIc",ENSG00000198569,Solute carrier family 34 member 3,9,137230757-137236554,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA023776,Enhanced,,,,,Mixed,Group enriched,15,kidney: 11.8;small intestine: 9.1,testis: 0.7,Cell line enhanced,,CAPAN-2: 2.9;MCF7: 4.2
45,CEACAM18,,ENSG00000213822,Carcinoembryonic antigen related cell adhesion molecule 18,19,51478622-51490952,Predicted secreted proteins,Evidence at protein level,HPA059487,Uncertain,,Approved,Midbody,,Tissue enhanced,Group enriched,14,duodenum: 10.5;small intestine: 7.2,gallbladder: 0.6,Group enriched,12.0,CACO-2: 3.6;RT4: 1.1
46,CHST5,"FLJ22167, I-GLCNAC-6-ST",ENSG00000135702,Carbohydrate sulfotransferase 5,16,75528535-75535247,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA043804,Enhanced,,,,,Group enriched,Group enriched,14,colon: 45.6;duodenum: 85.9;rectum: 59.7;small intestine: 83.5,stomach: 4.8,Mixed,,
47,FAM151A,"C1orf179, MGC27169",ENSG00000162391,Family with sequence similarity 151 member A,1,54609182-54623556,Predicted intracellular proteins,Evidence at protein level,HPA016840,Approved,,Uncertain,Nucleoplasm,Renal cancer:4.09e-5 (favourable),Group enriched,Group enriched,14,kidney: 175.3;small intestine: 66.8,liver: 8.5,Cell line enriched,41.0,CACO-2: 63.5
48,FAM25C,bA164N7.4,ENSG00000276430,Family with sequence similarity 25 member C,10,47995355-47999791,Predicted intracellular proteins,Evidence at transcript level,HPA044808,Uncertain,,,,,Tissue enhanced,Group enriched,14,breast: 5.3;esophagus: 4.0;skin: 9.0;small intestine: 4.3;tonsil: 2.1,"skeletal muscle,testis: 0.3",Cell line enriched,5.0,SK-BR-3: 12.1
49,GUCY2C,"GUC2C, STAR",ENSG00000070019,Guanylate cyclase 2C,12,14612632-14696585,"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA037655, HPA073759",Uncertain,,Uncertain,Vesicles,Liver cancer:1.37e-5 (unfavourable),Group enriched,Group enriched,13,colon: 37.0;duodenum: 68.7;rectum: 45.4;small intestine: 73.2,appendix: 4.4,Cell line enhanced,,AN3-CA: 1.2;CAPAN-2: 1.4;SiHa: 1.6
50,MYO1A,"DFNA48, MYHL",ENSG00000166866,Myosin IA,12,57028517-57051198,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA053490,Enhanced,,,,,Group enriched,Group enriched,13,colon: 67.8;duodenum: 333.2;rectum: 71.8;small intestine: 338.4,stomach: 16.1,Cell line enhanced,,BEWO: 1.9;CACO-2: 6.6;Hep G2: 3.7
51,NAT2,AAC2,ENSG00000156006,N-acetyltransferase 2,8,18391245-18401218,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043704,Uncertain,,,,Colorectal cancer:4.61e-5 (favourable),Tissue enhanced,Group enriched,13,colon: 14.4;duodenum: 32.7;liver: 62.4;rectum: 14.0;small intestine: 27.1,smooth muscle: 2.3,Cell line enhanced,,RT4: 1.2;SCLC-21H: 2.5;SK-BR-3: 1.0
52,NLRP6,"CLR11.4, NALP6, PAN3, PYPAF5",ENSG00000174885,NLR family pyrin domain containing 6,11,278365-285359,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043681, HPA048500",Supported,,,,Liver cancer:4.23e-5 (favourable),Mixed,Group enriched,13,duodenum: 39.4;small intestine: 40.2,appendix: 3.0,Cell line enhanced,,REH: 1.8;U-266/70: 2.8
53,CDHR2,"FLJ20124, FLJ20383, PC-LKC, PCDH24, PCLKC",ENSG00000074276,Cadherin related family member 2,5,176542511-176595974,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA012569, HPA017053",Enhanced,,,,Renal cancer:9.29e-4 (favourable),Group enriched,Group enriched,12,duodenum: 276.5;small intestine: 260.3,colon: 22.6,Cell line enriched,12.0,Hep G2: 15.0
54,FABP2,I-FABP,ENSG00000145384,Fatty acid binding protein 2,4,119317250-119322390,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034607, CAB047325, CAB047326",Enhanced,,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,,Group enriched,Group enriched,12,duodenum: 261.4;small intestine: 554.5,rectum: 33.8,Not detected,,
55,MOGAT2,"DGAT2L5, FLJ22644, MGAT2",ENSG00000166391,Monoacylglycerol O-acyltransferase 2,11,75717819-75732958,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA028834,Uncertain,,,,,Tissue enhanced,Group enriched,12,colon: 12.5;duodenum: 37.2;liver: 12.1;rectum: 12.5;small intestine: 43.6,appendix: 1.9,Group enriched,6.0,Hep G2: 2.7;RPMI-8226: 1.8
56,SLC39A5,,ENSG00000139540,Solute carrier family 39 member 5,12,56230049-56237846,"Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA018423,,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:5.05e-4 (favourable),Tissue enhanced,Group enriched,12,colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4,gallbladder: 10.0,Group enriched,62.0,CACO-2: 33.1;Hep G2: 39.7
57,XPNPEP2,,ENSG00000122121,X-prolyl aminopeptidase 2,X,129738974-129769538,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA000339, CAB025136, CAB025269",Enhanced,,,,,Group enriched,Group enriched,12,duodenum: 128.1;kidney: 175.9;small intestine: 231.5,liver: 14.3,Cell line enhanced,,ASC diff: 6.9;ASC TERT1: 36.6;HSkMC: 19.4
58,CYP2C18,"CPCI, CYP2C, CYP2C17, P450IIC17",ENSG00000108242,Cytochrome P450 family 2 subfamily C member 18,10,94683621-94736190,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,11,duodenum: 103.1;esophagus: 24.6;gallbladder: 24.5;liver: 97.8;small intestine: 88.1;stomach: 62.2,tonsil: 6.2,Cell line enhanced,,BEWO: 3.0
59,KHK,,ENSG00000138030,Ketohexokinase,2,27086747-27100772,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007040,Enhanced,,Approved,Cytosol,Endometrial cancer:7.62e-8 (unfavourable),Group enriched,Group enriched,11,duodenum: 113.1;kidney: 111.2;liver: 97.3;small intestine: 133.2,cerebral cortex: 10.1,Cell line enhanced,,Hep G2: 32.5
60,ABCC2,"CMOAT, cMRP, DJS, MRP2",ENSG00000023839,ATP binding cassette subfamily C member 2,10,99782732-99852192,"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA004860, CAB037271",Enhanced,,,,Renal cancer:1.93e-5 (unfavourable),Tissue enhanced,Group enriched,10,duodenum: 43.5;gallbladder: 42.7;kidney: 20.9;liver: 67.6;small intestine: 49.5,breast: 4.4,Cell line enhanced,,A549: 203.8;Hep G2: 155.8
61,CHP2,,ENSG00000166869,Calcineurin like EF-hand protein 2,16,23754627-23758951,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,CAB072806,Approved,,,,,Tissue enhanced,Group enriched,10,colon: 119.1;duodenum: 252.0;rectum: 127.6;skin: 143.8;small intestine: 227.3,"cervix, uterine: 17.1",Cell line enhanced,,hTERT-HME1: 4.5;NB-4: 4.6
62,HHLA2,"B7-H5, B7H7, B7y",ENSG00000114455,HERV-H LTR-associating 2,3,108296490-108378285,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA055478,Enhanced,,,,,Group enriched,Group enriched,10,colon: 87.7;duodenum: 87.1;gallbladder: 46.0;rectum: 90.5;small intestine: 143.9,stomach: 9.2,Cell line enhanced,,HDLM-2: 3.7;Karpas-707: 2.0
63,NR1I2,"BXR, ONR1, PAR2, PXR, SXR",ENSG00000144852,Nuclear receptor subfamily 1 group I member 2,3,119780484-119818485,"FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA029309, HPA055121, HPA073926",,,Enhanced,Nucleoplasm,,Group enriched,Group enriched,10,colon: 10.3;duodenum: 27.2;gallbladder: 6.4;liver: 20.0;rectum: 10.7;small intestine: 30.0,stomach: 1.7,Group enriched,7.0,Hep G2: 9.8;RH-30: 3.3
64,PLA2G12B,PLA2G13,ENSG00000138308,Phospholipase A2 group XIIB,10,72935170-72954778,"Plasma proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA057745, HPA059562",Approved,,Approved,Vesicles,,Tissue enriched,Group enriched,10,duodenum: 35.2;kidney: 19.0;liver: 49.9;small intestine: 45.9,lung: 3.9,Group enriched,6.0,CACO-2: 10.3;Hep G2: 14.2
65,SLC52A1,"FLJ10060, GPCR42, GPR172B, hRFT1, PAR2, RFVT1",ENSG00000132517,Solute carrier family 52 member 1,17,5032600-5052009,"Disease related genes, Predicted membrane proteins",Evidence at protein level,CAB011449,Uncertain,,,,Cervical cancer:9.54e-4 (favourable),Mixed,Group enriched,10,duodenum: 36.1;placenta: 26.1;skin: 13.2;small intestine: 26.3,parathyroid gland: 2.6,Cell line enhanced,,A549: 2.1;BEWO: 1.9;HMC-1: 4.1;SK-BR-3: 2.0
66,SLC5A1,"D22S675, NAGT, SGLT1",ENSG00000100170,Solute carrier family 5 member 1,22,32043032-32113029,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB015467, HPA051805, HPA055106",Enhanced,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable)",Mixed,Group enriched,10,duodenum: 505.0;small intestine: 313.4,gallbladder: 40.2,Cell line enhanced,,CACO-2: 2.1;RPMI-8226: 1.3;SH-SY5Y: 1.0
67,SLC6A4,"5-HTT, HTT, OCD1, SERT1",ENSG00000108576,Solute carrier family 6 member 4,17,30194319-30236002,"FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA071354, HPA074728",,Supported,Supported,Golgi apparatus<br>Vesicles,,Tissue enhanced,Group enriched,10,duodenum: 10.4;lung: 44.2;placenta: 26.4;small intestine: 45.3,esophagus: 3.1,Cell line enhanced,,BEWO: 1.9;CACO-2: 3.2;Hep G2: 7.1
68,SLC7A9,CSNU3,ENSG00000021488,Solute carrier family 7 member 9,19,32830509-32869766,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA042591,Enhanced,,,,,Group enriched,Group enriched,10,duodenum: 79.0;kidney: 70.1;small intestine: 123.5,liver: 8.9,Group enriched,20.0,BEWO: 3.3;CACO-2: 6.7;Hep G2: 5.4
69,ANPEP,"CD13, gp150, LAP1, p150, PEPN",ENSG00000166825,"Alanyl aminopeptidase, membrane",15,89784889-89815401,"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002417, HPA004625",Enhanced,,Supported,Plasma membrane,,Expressed in all,Group enriched,9,duodenum: 2386.4;small intestine: 2133.7,kidney: 263.2,Cell line enhanced,,BJ hTERT+: 958.3;HUVEC TERT2: 770.8;TIME: 760.6;U-2197: 926.0
70,ATOH1,"bHLHa14, HATH1, MATH-1, Math1",ENSG00000172238,Atonal bHLH transcription factor 1,4,93828753-93830964,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,Colorectal cancer:3.26e-5 (favourable),Tissue enhanced,Group enriched,9,colon: 17.6;duodenum: 11.1;rectum: 19.7;small intestine: 22.4,appendix: 1.9,Not detected,,
71,CDHR5,"FLJ20219, MU-PCDH, MUCDHL, MUPCDH",ENSG00000099834,Cadherin related family member 5,11,616565-626078,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA009081, HPA009173, CAB025004",Enhanced,,,,,Group enriched,Group enriched,9,colon: 41.7;duodenum: 82.7;kidney: 23.6;liver: 21.0;rectum: 54.3;small intestine: 64.3,gallbladder: 5.3,Cell line enhanced,,CACO-2: 2.1
72,CDX1,,ENSG00000113722,Caudal type homeobox 1,5,150166795-150184558,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA055196,Enhanced,,,,,Tissue enhanced,Group enriched,9,colon: 129.9;duodenum: 64.5;rectum: 134.7;small intestine: 104.9,appendix: 12.1,Cell line enhanced,,BJ hTERT+: 5.4;SH-SY5Y: 1.3
73,LRRC19,FLJ21302,ENSG00000184434,Leucine rich repeat containing 19,9,26993136-27005693,Predicted membrane proteins,Evidence at protein level,,,,,,Renal cancer:7.08e-8 (favourable),Group enriched,Group enriched,9,colon: 35.9;duodenum: 23.7;gallbladder: 9.4;kidney: 45.1;rectum: 35.3;small intestine: 34.7,appendix: 3.5,Not detected,,
74,NTS,,ENSG00000133636,Neurotensin,12,85874295-85882992,Predicted secreted proteins,Evidence at protein level,HPA026664,Enhanced,,,,"Cervical cancer:9.94e-5 (favourable), Endometrial cancer:5.10e-4 (unfavourable)",Tissue enhanced,Group enriched,9,small intestine: 189.6;stomach: 43.5,lymph node: 13.4,Cell line enhanced,,HEL: 45.5;NTERA-2: 10.8
75,REG1A,"PSP, PSPS, PSPS1, PTP, REG",ENSG00000115386,Regenerating family member 1 alpha,2,79120362-79123419,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB025138, HPA045549, HPA045579",Enhanced,,,,,Group enriched,Group enriched,9,duodenum: 7122.5;pancreas: 10867.0;small intestine: 4615.5,stomach: 847.5,Cell line enhanced,,BEWO: 11.1;EFO-21: 16.2;HDLM-2: 13.2;RPMI-8226: 20.2;SH-SY5Y: 12.6;U-2 OS: 28.7
76,REG4,"GISP, REG-IV, RELP",ENSG00000134193,Regenerating family member 4,1,119794018-119811660,Predicted secreted proteins,Evidence at protein level,"CAB025867, HPA046555",Enhanced,,,,,Group enriched,Group enriched,9,colon: 215.7;duodenum: 239.5;rectum: 299.4;small intestine: 664.5,appendix: 39.6,Group enriched,24.0,PC-3: 85.3;RT4: 20.5
77,SLC5A9,SGLT4,ENSG00000117834,Solute carrier family 5 member 9,1,48222685-48248644,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA050263,,,Approved,Actin filaments<br>Cytosol,Renal cancer:1.84e-5 (unfavourable),Tissue enhanced,Group enriched,9,duodenum: 42.6;small intestine: 45.5,lung: 4.6,Cell line enriched,7.0,Hep G2: 10.2
78,TMEM236,"bA162I21.2, bA16O1.2, FAM23A, FAM23B",ENSG00000148483,Transmembrane protein 236,10,17752252-17800868,Predicted membrane proteins,Evidence at protein level,HPA045096,Enhanced,,,,,Tissue enhanced,Group enriched,9,colon: 14.4;duodenum: 22.1;rectum: 15.5;small intestine: 37.7,appendix: 2.3,Cell line enriched,9.0,MOLT-4: 8.4
79,AQP10,,ENSG00000143595,Aquaporin 10,1,154321090-154325325,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA065947,Enhanced,,,,,Not detected,Group enriched,8,duodenum: 68.4;small intestine: 48.7,fallopian tube: 7.2,Group enriched,27.0,HEL: 16.1;HMC-1: 6.3;K-562: 18.7;SH-SY5Y: 5.0
80,CDH17,"cadherin, HPT-1",ENSG00000079112,Cadherin 17,8,94127171-94217303,"Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA023614, HPA023616, CAB025143, HPA026556",Enhanced,,Supported,Cell Junctions,,Group enriched,Group enriched,8,colon: 256.9;duodenum: 314.3;rectum: 267.3;small intestine: 294.3,appendix: 37.5,Group enriched,6.0,CACO-2: 81.5;U-266/70: 121.0
81,CLCA1,"CaCC, CLCRG1",ENSG00000016490,Chloride channel accessory 1,1,86468368-86500289,"Predicted secreted proteins, Transporters",Evidence at protein level,"HPA052787, HPA059301",Enhanced,,,,Colorectal cancer:2.98e-4 (favourable),Group enriched,Group enriched,8,colon: 699.6;duodenum: 882.2;rectum: 1126.3;small intestine: 1522.4,appendix: 133.7,Cell line enhanced,,BEWO: 1.9;NB-4: 1.5;RPMI-8226: 1.8;SH-SY5Y: 1.9;U-2197: 1.3
82,CLRN3,"MGC32871, TMEM12, USH3AL1",ENSG00000180745,Clarin 3,10,127877841-127892947,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA014482,Approved,,,,Stomach cancer:8.98e-4 (favourable),Group enriched,Group enriched,8,colon: 69.9;duodenum: 73.3;gallbladder: 23.6;kidney: 44.3;liver: 40.4;rectum: 76.3;small intestine: 97.5,appendix: 7.2,Cell line enriched,6.0,CACO-2: 1.9
83,CYP1A1,"CP11, CYP1, P1-450, P450-C, P450DX",ENSG00000140465,Cytochrome P450 family 1 subfamily A member 1,15,74719542-74725610,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB018654,Uncertain,,,,,Group enriched,Group enriched,8,liver: 33.9;small intestine: 20.5;urinary bladder: 80.8,breast: 5.7,Cell line enhanced,,CACO-2: 30.3;hTCEpi: 14.0;HUVEC TERT2: 15.7
84,DHRS11,"MGC4172, SDR24C1",ENSG00000278535,Dehydrogenase/reductase 11,17,36591798-36600806,Predicted intracellular proteins,Evidence at protein level,"HPA041226, HPA048236, HPA053623",Enhanced,,Approved,Golgi apparatus<br>Cytosol,Renal cancer:3.24e-4 (favourable),Expressed in all,Group enriched,8,colon: 44.6;duodenum: 149.5;rectum: 47.1;small intestine: 133.6,testis: 11.8,Mixed,,
85,GPA33,A33,ENSG00000143167,Glycoprotein A33,1,167052836-167166479,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018858, CAB025943",Enhanced,,,,,Tissue enriched,Group enriched,8,colon: 183.6;duodenum: 130.8;rectum: 188.7;small intestine: 131.3,appendix: 19.0,Cell line enhanced,,NTERA-2: 1.0
86,HTR1D,"5-HT1D, HT1DA, HTRL, RDC4",ENSG00000179546,5-hydroxytryptamine receptor 1D,1,23191895-23194729,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,"Liver cancer:1.86e-4 (unfavourable), Pancreatic cancer:5.30e-4 (unfavourable)",Mixed,Group enriched,8,duodenum: 9.4;gallbladder: 2.5;small intestine: 9.1,fallopian tube: 0.9,Cell line enhanced,,A549: 9.5;SiHa: 7.5;TIME: 21.6;U-2 OS: 9.0
87,MALRD1,"bA265G8.2, C10orf112, Diet1",ENSG00000204740,MAM and LDL receptor class A domain containing 1,10,19048771-19790401,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA035732, HPA038106, HPA046848",Uncertain,,Enhanced,Golgi apparatus,,Tissue enhanced,Group enriched,8,duodenum: 30.8;small intestine: 34.4,testis: 3.9,Cell line enriched,9.0,Karpas-707: 31.8
88,MUC17,,ENSG00000169876,"Mucin 17, cell surface associated",7,101020072-101058745,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,HPA031634,Enhanced,,,,,Group enriched,Group enriched,8,duodenum: 21.8;small intestine: 42.5,rectum: 3.8,Not detected,,
89,SLC2A7,GLUT7,ENSG00000197241,Solute carrier family 2 member 7,1,9003300-9026345,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA039931,Uncertain,,,,,Not detected,Group enriched,8,duodenum: 3.0;small intestine: 3.1,"epididymis,testis: 0.3",Not detected,,
90,SLC35G1,"C10orf60, FLJ33990, TMEM20",ENSG00000176273,Solute carrier family 35 member G1,10,93893973-93956062,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Mixed,Group enriched,8,duodenum: 86.0;small intestine: 44.8,"rectum,testis: 7.8",Mixed,,
91,SLC39A4,"AEZ, AWMS2, ZIP4",ENSG00000147804,Solute carrier family 39 member 4,8,144409742-144416895,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:9.04e-4 (favourable),Expressed in all,Group enriched,8,duodenum: 134.2;small intestine: 95.7,kidney: 14.3,Group enriched,9.0,CAPAN-2: 50.5;Hep G2: 102.1
92,SLC5A4,"DJ90G24.4, SAAT1, SGLT3",ENSG00000100191,Solute carrier family 5 member 4,22,32218476-32255341,"Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Tissue enriched,Group enriched,8,duodenum: 18.0;small intestine: 21.3,lung: 2.3,Cell line enriched,15.0,SK-MEL-30: 21.9
93,SMIM24,"C19orf77, HSPC323",ENSG00000095932,Small integral membrane protein 24,19,3473986-3480542,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA045046, HPA056027",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:4.13e-10 (favourable),Tissue enhanced,Group enriched,8,duodenum: 758.8;epididymis: 1928.7;kidney: 835.9;small intestine: 682.3,stomach: 140.0,Group enriched,8.0,CACO-2: 128.5;HEL: 66.3;Hep G2: 79.7;MOLT-4: 90.8;REH: 56.0;U-937: 68.2
94,C11orf86,FLJ22675,ENSG00000173237,Chromosome 11 open reading frame 86,11,66975277-66977004,Predicted intracellular proteins,Evidence at transcript level,HPA039348,Uncertain,,,,"Renal cancer:1.02e-5 (unfavourable), Pancreatic cancer:6.97e-5 (unfavourable), Lung cancer:8.97e-4 (unfavourable)",Mixed,Group enriched,7,duodenum: 68.2;small intestine: 70.9,colon: 10.3,Cell line enriched,5.0,SiHa: 26.4
95,EPS8L3,"FLJ21522, MGC16817",ENSG00000198758,EPS8 like 3,1,109750080-109764027,Predicted intracellular proteins,Evidence at protein level,HPA030998,Approved,,Approved,Vesicles,"Renal cancer:2.52e-5 (unfavourable), Liver cancer:4.13e-5 (unfavourable), Urothelial cancer:1.82e-4 (favourable)",Group enriched,Group enriched,7,colon: 75.0;duodenum: 152.1;gallbladder: 59.8;rectum: 86.1;small intestine: 167.1;stomach: 53.4,appendix: 15.1,Group enriched,12.0,CACO-2: 13.3;CAPAN-2: 13.3;EFO-21: 5.8;Hep G2: 25.0
96,ERN2,IRE1b,ENSG00000134398,Endoplasmic reticulum to nucleus signaling 2,16,23690326-23713500,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA016558,Uncertain,,,,,Mixed,Group enriched,7,"cervix, uterine: 27.6;colon: 27.5;duodenum: 12.3;gallbladder: 25.1;rectum: 23.2;small intestine: 9.9;stomach: 49.1",appendix: 3.8,Cell line enriched,8.0,CAPAN-2: 5.9
97,FABP1,L-FABP,ENSG00000163586,Fatty acid binding protein 1,2,88122982-88128116,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002305, HPA028275",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Group enriched,Group enriched,7,colon: 4552.0;duodenum: 4123.5;liver: 5672.8;rectum: 3081.5;small intestine: 4506.9,kidney: 602.3,Group enriched,6.0,CACO-2: 84.1;Hep G2: 221.3
98,GALNT8,GALNAC-T8,ENSG00000130035,Polypeptide N-acetylgalactosaminyltransferase 8,12,4720341-4851927,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012638, HPA014418, HPA073461",Approved,,Approved,Vesicles,,Tissue enhanced,Group enriched,7,cerebral cortex: 19.4;colon: 17.6;duodenum: 8.1;rectum: 40.6;small intestine: 18.9;testis: 26.5,appendix: 3.2,Cell line enhanced,,Karpas-707: 24.5;NTERA-2: 12.1;U-2 OS: 4.6;U-266/84: 7.3
99,HAPLN4,"BRAL2, KIAA1926",ENSG00000187664,Hyaluronan and proteoglycan link protein 4,19,19255641-19262796,Predicted secreted proteins,Evidence at protein level,HPA055856,Approved,,,,,Not detected,Group enriched,7,cerebral cortex: 8.4;duodenum: 15.3;small intestine: 21.2,"cervix, uterine: 2.1",Cell line enhanced,,NB-4: 2.6;NTERA-2: 10.4;SCLC-21H: 2.6
100,IGSF23,,ENSG00000216588,Immunoglobulin superfamily member 23,19,44613630-44636781,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA051811, HPA054591",Uncertain,,Approved,Nucleus<br>Cell Junctions,Liver cancer:7.20e-6 (favourable),Tissue enriched,Group enriched,7,duodenum: 15.2;liver: 13.0;small intestine: 17.4,testis: 2.3,Cell line enhanced,,CACO-2: 9.0;Hep G2: 4.4;SiHa: 5.2
101,PHGR1,,ENSG00000233041,"Proline, histidine and glycine rich 1",15,40351033-40356434,Predicted intracellular proteins,Evidence at protein level,HPA068787,Enhanced,,Approved,Vesicles,Breast cancer:2.05e-4 (favourable),Group enriched,Group enriched,7,colon: 1448.4;duodenum: 892.1;rectum: 399.5;small intestine: 1777.5,stomach: 166.8,Cell line enhanced,,BEWO: 12.3;HaCaT: 16.0;SCLC-21H: 72.5
102,PLB1,"FLJ30866, PLB",ENSG00000163803,Phospholipase B1,2,28457145-28643788,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA014045,,,Approved,Cytosol,,Mixed,Group enriched,7,skin: 9.4;small intestine: 45.7,testis: 4.2,Cell line enhanced,,BEWO: 3.5
103,PPP1R14D,"CPI17-like, FLJ20251, GBPI-1, MGC119014, MGC119016",ENSG00000166143,Protein phosphatase 1 regulatory inhibitor subunit 14D,15,40815445-40828709,Predicted intracellular proteins,Evidence at protein level,HPA041846,Uncertain,,,,Renal cancer:3.07e-4 (unfavourable),Tissue enhanced,Group enriched,7,colon: 105.5;duodenum: 111.1;gallbladder: 24.2;rectum: 100.0;small intestine: 89.8,appendix: 12.4,Cell line enhanced,,RPMI-8226: 2.1;RT4: 1.5;U-266/84: 1.4
104,REEP6,"C19orf32, DP1L1, FLJ25383, Yip2f",ENSG00000115255,Receptor accessory protein 6,19,1490747-1497927,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA003895, HPA048015",Enhanced,,Supported,Endoplasmic reticulum,,Expressed in all,Group enriched,7,adrenal gland: 48.2;duodenum: 166.1;liver: 76.1;small intestine: 167.0;testis: 181.2,prostate: 19.3,Cell line enhanced,,K-562: 101.6;T-47d: 84.9
105,SH2D7,LOC646892,ENSG00000183476,SH2 domain containing 7,15,78077808-78104909,Predicted intracellular proteins,Evidence at transcript level,HPA051320,Approved,,,,,Mixed,Group enriched,7,colon: 1.6;duodenum: 2.1;small intestine: 1.9;testis: 5.7,cerebral cortex: 0.4,Cell line enhanced,,SH-SY5Y: 1.4
106,SULT1E1,"EST, STE",ENSG00000109193,Sulfotransferase family 1E member 1,4,69810780-69860152,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028213, HPA028728, CAB047344",Enhanced,,Uncertain,Nuclear membrane<br>Cytosol,Cervical cancer:4.06e-4 (favourable),Mixed,Group enriched,7,duodenum: 27.7;liver: 18.7;skin: 7.6;small intestine: 29.7,adrenal gland: 3.1,Group enriched,17.0,HHSteC: 59.4;HSkMC: 23.3;hTCEpi: 19.7;HUVEC TERT2: 16.9
107,UGT1A5,UGT1E,ENSG00000240224,UDP glucuronosyltransferase family 1 member A5,2,233712992-233773299,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Group enriched,7,duodenum: 7.5;gallbladder: 3.9;small intestine: 6.8,liver: 0.9,Not detected,,
108,VIL1,"D2S1471, VIL",ENSG00000127831,Villin 1,2,218419092-218453295,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002452, HPA006884, HPA006885",Enhanced,,Enhanced,Plasma membrane,,Tissue enhanced,Group enriched,7,colon: 173.7;duodenum: 398.5;rectum: 199.6;small intestine: 480.0,gallbladder: 44.7,Group enriched,91.0,CACO-2: 628.4;Hep G2: 245.1
109,ZNF488,FLJ32104,ENSG00000265763,Zinc finger protein 488,10,47365496-47384273,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA035957, HPA035958, HPA044867",Uncertain,,Supported,Nucleoplasm<br>Cytosol,Pancreatic cancer:4.02e-7 (unfavourable),Mixed,Group enriched,7,cerebral cortex: 19.0;duodenum: 22.6;placenta: 4.8;small intestine: 12.1,"epididymis,skin: 2.0",Cell line enhanced,,HaCaT: 41.7;HDLM-2: 65.3;RT4: 30.6
110,ADGRG7,"FLJ14454, GPR128",ENSG00000144820,Adhesion G protein-coupled receptor G7,3,100609589-100695479,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,6,duodenum: 42.8;liver: 12.5;small intestine: 42.9,colon: 5.3,Not detected,,
111,AMN,amnionless,ENSG00000166126,Amnion associated transmembrane protein,14,102922656-102933596,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA000817,Approved,,,,Renal cancer:9.62e-5 (favourable),Mixed,Group enriched,6,colon: 20.0;duodenum: 34.2;kidney: 29.0;small intestine: 70.6,liver: 6.7,Cell line enhanced,,CACO-2: 6.8;Hep G2: 5.6;U-698: 3.0
112,BTNL8,"BTN9.2, FLJ21458",ENSG00000113303,Butyrophilin like 8,5,180899077-180950906,Predicted membrane proteins,Evidence at protein level,HPA039738,Approved,,,,,Group enriched,Group enriched,6,colon: 26.1;duodenum: 117.4;rectum: 27.7;small intestine: 94.2,gallbladder: 10.4,Cell line enriched,26.0,CACO-2: 31.4
113,C8G,,ENSG00000176919,Complement C8 gamma chain,9,136945246-136946974,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA046269,Approved,,Uncertain,Endoplasmic reticulum,Colorectal cancer:2.99e-4 (unfavourable),Tissue enriched,Group enriched,6,duodenum: 49.8;liver: 106.5;small intestine: 34.5,gallbladder: 9.8,Cell line enriched,16.0,HMC-1: 139.2
114,CASP5,ICE(rel)III,ENSG00000137757,Caspase 5,11,104994235-105023168,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA040937,Uncertain,,,,,Group enriched,Group enriched,6,appendix: 20.2;colon: 15.9;duodenum: 10.1;rectum: 14.5;small intestine: 18.9,smooth muscle: 2.7,Cell line enriched,8.0,HHSteC: 3.1
115,CCR9,"CDw199, GPR-9-6, GPR28",ENSG00000173585,C-C motif chemokine receptor 9,3,45886504-45903177,"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB006839,Uncertain,,,,,Not detected,Group enriched,6,appendix: 1.4;duodenum: 3.8;small intestine: 5.7;spleen: 1.2,"lymph node,tonsil: 0.4",Cell line enriched,362.0,MOLT-4: 90.5
116,CDX2,CDX3,ENSG00000165556,Caudal type homeobox 2,13,27962137-27971139,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB002221, HPA045669, HPA049580",Enhanced,,Supported,Nucleoplasm,,Tissue enriched,Group enriched,6,colon: 30.8;duodenum: 22.3;rectum: 24.9;small intestine: 30.2,appendix: 4.7,Cell line enhanced,,CACO-2: 9.4;CAPAN-2: 3.3;HEK93: 5.6
117,CYP4F2,,ENSG00000186115,Cytochrome P450 family 4 subfamily F member 2,19,15878023-15898120,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA014048, HPA017265, HPA058960",Supported,,,,,Tissue enriched,Group enriched,6,duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3,prostate: 10.4,Cell line enhanced,,Hep G2: 2.5
118,EFNA2,"ELF-1, EPLG6, LERK6",ENSG00000099617,Ephrin A2,19,1286154-1300237,"Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB005178, HPA067567",Uncertain,,Approved,Mitochondria<br>Cytosol,,Tissue enhanced,Group enriched,6,colon: 7.0;duodenum: 7.9;small intestine: 10.6,rectum: 1.5,Cell line enhanced,,Hep G2: 6.6;NTERA-2: 5.4;REH: 6.8;SH-SY5Y: 17.8;U-2 OS: 5.8
119,FOLH1,"FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA",ENSG00000086205,Folate hydrolase 1,11,49146635-49208670,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB001451, HPA010593",Enhanced,,,,"Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable)",Tissue enriched,Group enriched,6,duodenum: 298.8;prostate: 136.6;small intestine: 90.8,cerebral cortex: 31.0,Mixed,,
120,HNF4A,"HNF4, MODY, MODY1, NR2A1, TCF14",ENSG00000101076,Hepatocyte nuclear factor 4 alpha,20,44355700-44434596,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA004712, CAB019417",Enhanced,,Supported,Nucleoplasm,,Tissue enhanced,Group enriched,6,colon: 58.0;duodenum: 103.0;kidney: 44.7;liver: 51.0;rectum: 47.8;small intestine: 90.9;stomach: 21.9,gallbladder: 9.2,Group enriched,8.0,CACO-2: 126.0;Hep G2: 77.0
121,IHH,"BDA1, HHG2",ENSG00000163501,Indian hedgehog,2,219054420-219060467,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Endometrial cancer:3.67e-6 (favourable),Tissue enhanced,Group enriched,6,"cervix, uterine: 8.9;colon: 21.0;duodenum: 14.9;endometrium: 31.4;rectum: 16.7;small intestine: 16.5;stomach: 15.3",prostate: 3.2,Cell line enriched,11.0,CACO-2: 16.8
122,LINC01207,,ENSG00000248771,Long intergenic non-protein coding RNA 1207,4,164754064-164803795,Predicted secreted proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,6,"cervix, uterine: 4.4;colon: 6.3;duodenum: 10.5;gallbladder: 6.2;prostate: 9.0;rectum: 7.8;small intestine: 12.4",appendix: 1.4,Not detected,,
123,MISP,"C19orf21, Caprice, DKFZp686H18209, MISP1",ENSG00000099812,Mitotic spindle positioning,19,751126-764318,Predicted intracellular proteins,Evidence at protein level,"HPA049511, HPA062232",Enhanced,,Enhanced,Plasma membrane<br>Focal adhesion sites,,Tissue enhanced,Group enriched,6,colon: 94.7;duodenum: 173.3;rectum: 52.6;small intestine: 217.1,stomach: 21.6,Cell line enhanced,,A549: 110.0;HaCaT: 79.4;hTCEpi: 59.7;SK-BR-3: 101.1
124,MOGAT3,"DC7, DGAT2L2, MGAT3",ENSG00000106384,Monoacylglycerol O-acyltransferase 3,7,101195007-101201021,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA011940,Uncertain,,Approved,Centrosome,,Tissue enhanced,Group enriched,6,colon: 11.3;duodenum: 30.4;rectum: 11.9;small intestine: 33.6,liver: 3.4,Cell line enhanced,,CACO-2: 2.9;Hep G2: 8.1
125,MUC13,DRCC1,ENSG00000173702,"Mucin 13, cell surface associated",3,124905442-124953819,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA045163,Enhanced,,,,Renal cancer:9.73e-5 (unfavourable),Tissue enhanced,Group enriched,6,colon: 301.8;duodenum: 614.7;rectum: 330.1;small intestine: 555.7,appendix: 79.5,Cell line enhanced,,A549: 6.6;CACO-2: 5.3;CAPAN-2: 11.9;Karpas-707: 5.6
126,NEU4,,ENSG00000204099,Neuraminidase 4,2,241808825-241817413,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037394, HPA037395",Uncertain,,,,,Group enriched,Group enriched,6,bone marrow: 2.4;cerebral cortex: 6.3;colon: 8.3;duodenum: 5.6;liver: 4.1;rectum: 3.7;small intestine: 5.3,"fallopian tube,gallbladder: 0.7",Group enriched,20.0,Hep G2: 26.3;HMC-1: 45.5
127,PCK2,"PEPCK, PEPCK2",ENSG00000100889,"Phosphoenolpyruvate carboxykinase 2, mitochondrial",14,24094053-24110598,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB018734, HPA051162, HPA053502",Enhanced,,Enhanced,Mitochondria,Liver cancer:2.81e-4 (favourable),Expressed in all,Group enriched,6,duodenum: 367.6;kidney: 192.2;liver: 258.6;small intestine: 276.5,colon: 47.0,Expressed in all,,
128,PRAP1,UPA,ENSG00000165828,Proline rich acidic protein 1,10,133347146-133352683,Predicted secreted proteins,Evidence at protein level,"HPA038713, HPA052451",Supported,,Uncertain,Nucleoplasm<br>Vesicles<br>Plasma membrane,,Group enriched,Group enriched,6,duodenum: 928.6;liver: 297.4;small intestine: 1097.7,kidney: 125.6,Group enriched,5.0,CACO-2: 18.2;Hep G2: 64.2
129,SCT,,ENSG00000070031,Secretin,11,626431-627143,Predicted secreted proteins,Evidence at protein level,HPA050961,Enhanced,,,,Colorectal cancer:3.70e-4 (unfavourable),Mixed,Group enriched,6,duodenum: 34.9;small intestine: 7.8,spleen: 3.4,Cell line enhanced,,HSkMC: 1.1
130,SDR16C5,"EPHD-2, RDH-E2, RDHE2",ENSG00000170786,Short chain dehydrogenase/reductase family 16C member 5,8,56300010-56320776,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA025224,Enhanced,,,,Head and neck cancer:7.88e-4 (favourable),Mixed,Group enriched,6,breast: 15.2;esophagus: 36.3;lung: 40.3;skin: 72.9;small intestine: 21.7;stomach: 21.0;tonsil: 25.3,"cervix, uterine: 5.6",Cell line enhanced,,CAPAN-2: 22.6;HaCaT: 11.3;hTCEpi: 15.1;T-47d: 9.2
131,SLC17A4,KIAA2138,ENSG00000146039,Solute carrier family 17 member 4,6,25754699-25781191,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA055564,Approved,,,,,Group enriched,Group enriched,6,colon: 20.4;duodenum: 28.6;gallbladder: 25.4;liver: 22.3;rectum: 28.9;small intestine: 35.0,pancreas: 4.2,Cell line enriched,5.0,RPTEC TERT1: 1.1
132,SPINK4,"MGC133107, PEC-60",ENSG00000122711,"Serine peptidase inhibitor, Kazal type 4",9,33218365-33248567,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007286,Enhanced,,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,Colorectal cancer:8.85e-5 (favourable),Group enriched,Group enriched,6,colon: 631.8;duodenum: 266.4;rectum: 1071.3;small intestine: 734.5,appendix: 107.1,Cell line enriched,8.0,HMC-1: 152.9
133,TMEM253,"C14orf176, C14orf95, NCRNA00220",ENSG00000232070,Transmembrane protein 253,14,21098937-21103724,Predicted membrane proteins,Evidence at protein level,"HPA052329, HPA065092",Enhanced,,,,,Mixed,Group enriched,6,duodenum: 101.3;small intestine: 100.0,colon: 15.8,Mixed,,
134,TPH1,"TPH, TPRH",ENSG00000129167,Tryptophan hydroxylase 1,11,18017564-18042426,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB010767, HPA022483",Enhanced,,Uncertain,Cytosol,,Mixed,Group enriched,6,colon: 8.8;duodenum: 10.2;rectum: 21.0;small intestine: 12.6;stomach: 15.5,prostate: 2.4,Mixed,,
135,TRIM31,"C6orf13, HCG1, HCGI, RNF",ENSG00000204616,Tripartite motif containing 31,6,30102897-30113106,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046400,Uncertain,,,,,Group enriched,Group enriched,6,colon: 10.0;small intestine: 2.3;stomach: 2.1;urinary bladder: 2.7,duodenum: 0.7,Cell line enriched,527.0,RT4: 232.7
136,URAD,PRHOXNB,ENSG00000183463,Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase,13,27977714-27988654,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA038972,Uncertain,,,,,Tissue enriched,Group enriched,6,colon: 12.6;duodenum: 8.3;small intestine: 17.9,appendix: 2.3,Group enriched,12.0,BEWO: 2.6;CACO-2: 2.1
137,ZG16,"hZG16, JCLN, JCLN1, ZG16A",ENSG00000174992,Zymogen granule protein 16,16,29778240-29782973,Predicted secreted proteins,Evidence at protein level,"HPA052066, HPA052512",Enhanced,,,,,Tissue enriched,Group enriched,6,colon: 363.4;rectum: 502.4;small intestine: 121.4,duodenum: 57.7,Cell line enhanced,,SK-BR-3: 1.7
138,AADAC,"CES5A1, DAC",ENSG00000114771,Arylacetamide deacetylase,3,151814037-151828488,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA002911,Approved,,,,"Ovarian cancer:5.58e-6 (favourable), Stomach cancer:2.19e-4 (unfavourable), Pancreatic cancer:5.02e-4 (unfavourable)",Tissue enriched,Group enriched,5,adrenal gland: 150.1;duodenum: 182.4;liver: 386.8;small intestine: 215.8,stomach: 43.5,Cell line enhanced,,A549: 7.3;EFO-21: 3.9;HBEC3-KT: 2.7
139,AC004754.3,,ENSG00000269881,,16,249547-269943,Predicted membrane proteins,Evidence at transcript level,"HPA011651, HPA071871",Uncertain,,Uncertain,Nucleoplasm<br>Mitochondria,,Not detected,Group enriched,5,duodenum: 14.2;small intestine: 7.8,testis: 2.0,Cell line enhanced,,EFO-21: 1.5
140,ACE2,,ENSG00000130234,Angiotensin I converting enzyme 2,X,15561033-15602148,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA000288, CAB026174",Enhanced,,,,"Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable)",Tissue enhanced,Group enriched,5,duodenum: 181.1;gallbladder: 100.2;kidney: 94.0;small intestine: 261.1;testis: 93.0,heart muscle: 27.9,Cell line enhanced,,HaCaT: 1.1
141,ACY1,,ENSG00000243989,Aminoacylase 1,3,51983278-51989202,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003695, HPA036174, HPA036175",Enhanced,,,,"Renal cancer:2.93e-4 (favourable), Urothelial cancer:6.77e-4 (favourable)",Expressed in all,Group enriched,5,duodenum: 130.8;kidney: 356.0;liver: 114.9;small intestine: 103.3,parathyroid gland: 35.0,Mixed,,
142,AKR7A3,,ENSG00000162482,Aldo-keto reductase family 7 member A3,1,19282558-19289250,Predicted intracellular proteins,Evidence at protein level,HPA064638,,,Approved,Cytosol,Renal cancer:8.80e-7 (favourable),Group enriched,Group enriched,5,duodenum: 170.4;gallbladder: 38.7;kidney: 49.0;liver: 44.8;small intestine: 106.8;stomach: 70.3,colon: 15.9,Cell line enhanced,,SK-BR-3: 12.6
143,ANXA13,ANX13,ENSG00000104537,Annexin A13,8,123680794-123737407,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA018535, HPA019569, HPA019650, CAB025135",Enhanced,,Supported,Plasma membrane,,Group enriched,Group enriched,5,duodenum: 296.6;fallopian tube: 92.7;gallbladder: 227.6;small intestine: 235.6,rectum: 39.2,Group enriched,16.0,A549: 25.3;HDLM-2: 13.7
144,B3GALT5,"B3GalT-V, B3T5, beta3Gal-T5, GLCT5",ENSG00000183778,"Beta-1,3-galactosyltransferase 5",21,39556442-39673137,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054092, HPA054684",Approved,,,,Endometrial cancer:6.36e-4 (favourable),Mixed,Group enriched,5,colon: 22.7;duodenum: 27.5;gallbladder: 8.6;rectum: 40.5;small intestine: 37.2,stomach: 5.0,Group enriched,5.0,CAPAN-2: 20.6;NTERA-2: 6.3;RPTEC TERT1: 20.7;SCLC-21H: 5.4
145,CYP2D6,"CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D",ENSG00000100197,Cytochrome P450 family 2 subfamily D member 6,22,42126499-42130906,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045223,Enhanced,,Approved,Golgi apparatus,,Tissue enriched,Group enriched,5,duodenum: 3.7;liver: 10.0;small intestine: 13.0,testis: 1.7,Cell line enhanced,,Hep G2: 1.2;HMC-1: 2.2;REH: 1.4;U-266/70: 1.3
146,DHDH,HUM2DD,ENSG00000104808,Dihydrodiol dehydrogenase,19,48933682-48944969,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044131,Approved,,Approved,Nucleoplasm<br>Actin filaments,"Renal cancer:3.15e-4 (favourable), Endometrial cancer:9.91e-4 (unfavourable)",Expressed in all,Group enriched,5,duodenum: 10.2;kidney: 17.8;prostate: 5.1;small intestine: 18.6,testis: 2.5,Cell line enhanced,,SCLC-21H: 2.5
147,ENPEP,"CD249, gp160",ENSG00000138792,Glutamyl aminopeptidase,4,110365733-110565285,"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA002821, HPA005128",Enhanced,,Approved,Endoplasmic reticulum,,Tissue enriched,Group enriched,5,duodenum: 36.5;kidney: 94.3;parathyroid gland: 160.7;small intestine: 180.3,placenta: 21.5,Cell line enhanced,,BEWO: 2.6;HEK93: 6.8;MOLT-4: 1.4
148,FOXA3,HNF3G,ENSG00000170608,Forkhead box A3,19,45863989-45873797,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB015154, HPA054034",Uncertain,,Approved,Nucleoplasm,,Mixed,Group enriched,5,colon: 16.7;duodenum: 10.3;liver: 32.5;pancreas: 9.8;rectum: 17.9;small intestine: 13.9;stomach: 33.8,gallbladder: 3.6,Cell line enhanced,,CACO-2: 8.4;HDLM-2: 11.2;Hep G2: 18.9;K-562: 20.1;NTERA-2: 10.8
149,HNF4G,NR2A2,ENSG00000164749,Hepatocyte nuclear factor 4 gamma,8,75407914-75566843,"Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA005438,Enhanced,,,,,Mixed,Group enriched,5,duodenum: 100.2;small intestine: 125.6,rectum: 21.0,Cell line enhanced,,A549: 3.8;CAPAN-2: 13.9;PC-3: 4.4
150,IL22RA1,"CRF2-9, IL22R",ENSG00000142677,Interleukin 22 receptor subunit alpha 1,1,24119771-24143121,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,5,colon: 11.3;duodenum: 20.2;esophagus: 10.1;pancreas: 26.1;rectum: 10.9;skin: 38.7;small intestine: 31.3,gallbladder: 4.0,Cell line enhanced,,CACO-2: 9.3;HaCaT: 4.5;Hep G2: 5.5
151,KCNJ13,"Kir1.4, Kir7.1, LCA16",ENSG00000115474,Potassium voltage-gated channel subfamily J member 13,2,232766464-232776568,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,5,parathyroid gland: 25.8;small intestine: 112.2,thyroid gland: 12.5,Cell line enhanced,,U-2197: 1.2
152,LRRC31,FLJ23259,ENSG00000114248,Leucine rich repeat containing 31,3,169839179-169869930,Predicted intracellular proteins,Evidence at protein level,HPA037548,Uncertain,,,,,Mixed,Group enriched,5,colon: 18.2;duodenum: 8.8;rectum: 24.3;small intestine: 11.0;stomach: 9.8,liver: 2.8,Cell line enhanced,,EFO-21: 1.8;HAP1: 1.4;RPTEC TERT1: 1.6
153,MGAM2,,ENSG00000257743,Maltase-glucoamylase 2 (putative),7,142111749-142222324,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA055697,Enhanced,,Approved,Vesicles<br>Cytosol,,Group enriched,Group enriched,5,duodenum: 11.8;small intestine: 10.4,salivary gland: 2.1,Cell line enriched,7.0,RH-30: 1.1
154,MYRFL,"bcm1377, C12orf15, C12orf28, FLJ25056",ENSG00000166268,Myelin regulatory factor-like,12,69825304-69959097,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA049340,Approved,,Approved,Nucleoli,,Mixed,Group enriched,5,duodenum: 23.7;small intestine: 24.0,testis: 4.3,Cell line enhanced,,NTERA-2: 5.2;T-47d: 11.1
155,NOS2,"HEP-NOS, iNOS, NOS, NOS2A",ENSG00000007171,Nitric oxide synthase 2,17,27756766-27800499,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB002014,Approved,,,,,Tissue enhanced,Group enriched,5,appendix: 18.9;colon: 7.0;duodenum: 12.3;rectum: 9.8;small intestine: 24.1;urinary bladder: 6.5,smooth muscle: 2.5,Group enriched,8.0,CACO-2: 13.0;SCLC-21H: 14.7
156,SLC15A1,"HPECT1, HPEPT1, PEPT1",ENSG00000088386,Solute carrier family 15 member 1,13,98683801-98752654,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA002827,Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,5,duodenum: 153.2;gallbladder: 67.7;small intestine: 225.0,skin: 27.8,Group enriched,6.0,CAPAN-2: 49.1;SK-BR-3: 41.2
157,SLC23A1,"SLC23A2, SVCT1, YSPL3",ENSG00000170482,Solute carrier family 23 member 1,5,139367196-139384553,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA047612,Enhanced,,,,,Group enriched,Group enriched,5,duodenum: 26.7;fallopian tube: 86.2;kidney: 41.9;small intestine: 72.0,liver: 10.7,Cell line enhanced,,CACO-2: 7.7;HDLM-2: 7.6;Hep G2: 9.2;Karpas-707: 7.8;RPMI-8226: 7.6;U-266/70: 12.7
158,SLC5A11,"KST1, SGLT6, SMIT2",ENSG00000158865,Solute carrier family 5 member 11,16,24845841-24911628,Predicted membrane proteins,Evidence at protein level,HPA035331,Uncertain,,Approved,Nucleus<br>Cytosol,,Mixed,Group enriched,5,cerebral cortex: 10.5;duodenum: 6.6;kidney: 6.1;small intestine: 15.2,breast: 1.7,Cell line enhanced,,BEWO: 1.7;Hep G2: 11.2;Karpas-707: 3.2
159,SMLR1,,ENSG00000256162,Small leucine rich protein 1,6,130827406-130837135,Predicted membrane proteins,Evidence at protein level,HPA066060,Uncertain,,,,,Tissue enriched,Group enriched,5,duodenum: 12.2;liver: 28.9;small intestine: 11.4,kidney: 3.2,Cell line enriched,10.0,Hep G2: 55.1
160,SOAT2,ACAT2,ENSG00000167780,Sterol O-acyltransferase 2,12,53103518-53124538,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,5,duodenum: 12.1;small intestine: 22.0,spleen: 3.2,Cell line enhanced,,CACO-2: 8.8;Hep G2: 15.8;U-266/70: 5.6
161,SULT1B1,ST1B2,ENSG00000173597,Sulfotransferase family 1B member 1,4,69721162-69787961,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA002107,Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus,,Group enriched,Group enriched,5,colon: 68.9;duodenum: 99.0;rectum: 67.1;small intestine: 103.7;stomach: 41.6,appendix: 13.8,Group enriched,6.0,HUVEC TERT2: 92.0;TIME: 29.6;U-2197: 29.2
162,TM4SF5,,ENSG00000142484,Transmembrane 4 L six family member 5,17,4771884-4783213,Predicted membrane proteins,Evidence at protein level,HPA055674,,,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,,Tissue enriched,Group enriched,5,duodenum: 176.7;small intestine: 168.8,liver: 33.3,Group enriched,13.0,CACO-2: 45.1;Hep G2: 64.9
163,TM6SF2,Lpr4,ENSG00000213996,Transmembrane 6 superfamily member 2,19,19264364-19273391,Predicted membrane proteins,Evidence at protein level,HPA066026,Uncertain,,,,,Tissue enhanced,Group enriched,5,duodenum: 77.0;small intestine: 76.8,liver: 14.7,Cell line enhanced,,HHSteC: 1.6;LHCN-M2: 1.2;SH-SY5Y: 1.8
164,TMEM132E,DFNB99,ENSG00000181291,Transmembrane protein 132E,17,34580749-34639318,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA070608,Approved,,,,Renal cancer:1.55e-4 (unfavourable),Group enriched,Group enriched,5,cerebral cortex: 4.8;duodenum: 1.7;kidney: 3.2;small intestine: 1.0;testis: 1.5,"cervix, uterine: 0.4",Cell line enriched,7.0,RPMI-8226: 31.6
165,TRPM5,"LTRPC5, MTR1",ENSG00000070985,Transient receptor potential cation channel subfamily M member 5,11,2404515-2423045,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA042115, HPA043315",Uncertain,,,,,Tissue enhanced,Group enriched,5,colon: 1.0;duodenum: 2.9;epididymis: 2.2;seminal vesicle: 2.5;small intestine: 2.9,"testis,thyroid gland: 0.4",Not detected,,
166,VIP,,ENSG00000146469,Vasoactive intestinal peptide,6,152750798-152759765,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA017324, CAB018649, HPA072701",Supported,,Approved,Endoplasmic reticulum,,Group enriched,Group enriched,5,appendix: 209.4;colon: 71.4;rectum: 68.3;small intestine: 52.7;smooth muscle: 58.1,duodenum: 16.8,Cell line enhanced,,SH-SY5Y: 2.8;TIME: 1.6
167,VNN1,Tiff66,ENSG00000112299,Vanin 1,6,132681590-132714049,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA064145,Approved,,,,Renal cancer:2.52e-4 (unfavourable),Tissue enhanced,Group enriched,5,duodenum: 171.4;gallbladder: 174.7;liver: 142.4;small intestine: 106.3,kidney: 27.5,Cell line enhanced,,EFO-21: 10.3
